Literature DB >> 7492114

Activities of three investigational fluoroquinolones (BAY y 3118, DU-6859a, and clinafloxacin) against Neisseria gonorrhoeae isolates with diminished susceptibilities to ciprofloxacin and ofloxacin.

C J Carlyn1, L J Doyle, C C Knapp, M D Ludwig, J A Washington.   

Abstract

Between 1 January 1992 and 31 December 1993, our laboratory, as part of the Gonococcal Isolate Surveillance Project, found that 39 of 673 isolates of Neisseria gonorrhoeae from one local sexually transmitted diseases clinic demonstrated decreased susceptibilities to both ciprofloxacin and ofloxacin. The MICs of BAY y 3118, DU-6859a, and clinafloxacin at which 90% of the gonococci with decreased susceptibility to ciprofloxacin and ofloxacin were inhibited were all 0.016 microgram/ml, which was eightfold higher than those for ciprofloxacin-susceptible gonococci. Our report substantiates prior observations that diminished susceptibility to one quinolone is often associated with diminished susceptibility to other quinolones.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7492114      PMCID: PMC162791          DOI: 10.1128/AAC.39.7.1606

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  15 in total

1.  Interpretive criteria for susceptibility testing of CI-960 (PD127391, AM-1091), fleroxacin, lomefloxacin, and temafloxacin against Neisseria gonorrhoeae, including drug stability in GC agar medium.

Authors:  M E Erwin; R N Jones
Journal:  J Clin Microbiol       Date:  1992-05       Impact factor: 5.948

2.  In vitro antibiotic susceptibilities of Neisseria gonorrhoeae isolates in the Philippines.

Authors:  T E Clendennen; C S Hames; E S Kees; F C Price; W J Rueppel; A B Andrada; G E Espinosa; G Kabrerra; F S Wignall
Journal:  Antimicrob Agents Chemother       Date:  1992-02       Impact factor: 5.191

3.  4-Quinolone-resistant Neisseria gonorrhoeae in the United Kingdom.

Authors:  W R Gransden; C Warren; I Phillips
Journal:  J Med Microbiol       Date:  1991-01       Impact factor: 2.472

4.  Norfloxacin resistant Neisseria gonorrhoeae in North America.

Authors:  K H Yeung; J R Dillon
Journal:  Lancet       Date:  1990-09-22       Impact factor: 79.321

5.  Ciprofloxacin resistance in gonococci.

Authors:  A E Jephcott; A Turner
Journal:  Lancet       Date:  1990-01-20       Impact factor: 79.321

6.  Interpretive criteria for susceptibility tests with DU-6859a and FK-037 tested against Haemophilus influenzae and Neisseria gonorrhoeae.

Authors:  R N Jones; M S Barrett; D J Biedenbach
Journal:  Diagn Microbiol Infect Dis       Date:  1994-06       Impact factor: 2.803

7.  Proposed interpretive criteria and quality control parameters for testing in vitro susceptibility of Neisseria gonorrhoeae to ciprofloxacin.

Authors:  P C Fuchs; A L Barry; C Baker; P R Murray; J A Washington
Journal:  J Clin Microbiol       Date:  1991-10       Impact factor: 5.948

8.  Effectiveness of norfloxacin and ofloxacin for treatment of gonorrhoea and decrease of in vitro susceptibility to quinolones over time in Rwanda.

Authors:  J Bogaerts; W M Tello; J Akingeneye; V Mukantabana; E Van Dyck; P Piot
Journal:  Genitourin Med       Date:  1993-06

9.  Resistance of recent Neisseria gonorrhoeae isolates in Nigeria and outcome of single-dose treatment with ciprofloxacin.

Authors:  J A Otubu; G E Imade; A S Sagay; O A Towobola
Journal:  Infection       Date:  1992 Nov-Dec       Impact factor: 3.553

10.  Characteristics of Neisseria gonorrhoeae isolated in Australia showing decreased sensitivity to quinolone antibiotics.

Authors:  J W Tapsall; T R Shultz; E A Phillips
Journal:  Pathology       Date:  1992-01       Impact factor: 5.306

View more
  4 in total

Review 1.  Quinolones in sexually transmitted diseases: state of the art.

Authors:  G L Ridgway
Journal:  Drugs       Date:  1999       Impact factor: 9.546

Review 2.  Concurrent gonococcal and chlamydial infection: how best to treat.

Authors:  A J Robinson; G L Ridgway
Journal:  Drugs       Date:  2000-04       Impact factor: 9.546

3.  In vitro activities of clinafloxacin against contemporary clinical bacterial isolates from 10 North American centers.

Authors:  P C Fuchs; A L Barry; S D Brown
Journal:  Antimicrob Agents Chemother       Date:  1998-05       Impact factor: 5.191

4.  DNA topoisomerase targets of the fluoroquinolones: a strategy for avoiding bacterial resistance.

Authors:  X Zhao; C Xu; J Domagala; K Drlica
Journal:  Proc Natl Acad Sci U S A       Date:  1997-12-09       Impact factor: 11.205

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.